Emergent BioSolutions (EBS) EPS (Basic) (2011 - 2026)

Emergent BioSolutions' EPS (Basic) history runs 15 years deep, the most recent figure standing at $0.13 for Q1 2026.

• On a quarterly basis, EPS (Basic) fell 89.52% year-over-year to $0.13 in Q1 2026; TTM through Mar 2026 was -$0.17, a 93.15% increase from a year earlier, with the FY2025 full-year figure at $0.98, up 127.34% from the prior year.
• EPS (Basic) climbed to $0.13 in Q1 2026 per EBS's latest filing, from -$1.02 in the prior quarter.
• Across five years, EPS (Basic) topped out at $2.16 in Q3 2024 and bottomed at -$5.38 in Q2 2024.
• The 5-year median for EPS (Basic) is -$0.97 (2023), against an average of -$1.28.
• Across the five-year window, EPS (Basic) tumbled 4982.56% in 2023 and jumped 625.0% in 2025, its largest moves.
• Year by year, EPS (Basic) stood at -$1.34 in 2022, then climbed by 27.71% to -$0.97 in 2023, then soared by 38.92% to -$0.59 in 2024, then slumped by 72.81% to -$1.02 in 2025, then soared by 112.84% to $0.13 in 2026.
• Per Business Quant, the three latest EBS EPS (Basic) figures stand at $0.13 (Q1 2026), -$1.02 (Q4 2025), and $0.96 (Q3 2025).